1. Search Result
Search Result
Results for "

cluster of differentiation 47 (CD47)

" in MedChemExpress (MCE) Product Catalog:

349

Inhibitors & Agonists

3

Screening Libraries

10

Fluorescent Dye

40

Biochemical Assay Reagents

36

Peptides

26

Inhibitory Antibodies

64

Natural
Products

188

Recombinant Proteins

13

Isotope-Labeled Compounds

92

Antibodies

3

Click Chemistry

7

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P990131

    CD47 Others
    Anti-Mouse CD47/IAP Antibody (MIAP301) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD47/IAP.
    Anti-Mouse CD47/IAP Antibody (MIAP301)
  • HY-P99172

    CD47 Interleukin Related Cancer
    CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar Kd value. CC-90002 can be used for the research of hematologic malignancies and solid tumors .
    CC-90002
  • HY-P990132

    CD47 Others
    Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human CD47/IAP.
    Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410)
  • HY-P99533

    SRF-231; SRF231

    CD47 Interleukin Related Cancer
    Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction .
    Urabrelimab
  • HY-143224B

    CD47 Cancer
    NCGC00138783 TFA is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 μM. NCGC00138783 TFA directly blocks the interaction between CD47 and SIRPα axis .
    NCGC00138783 TFA
  • HY-115983

    CD47 Apoptosis Cancer
    DMUP is a potent CD47-SIRPα axis inhibitor. DMUP induces apoptosis and increases the macrophage phagocytosis in A549 cells. DMUP decreases the expression of CD47 and SIRPα protein. DMUP shows antitumor activity .
    DMUP
  • HY-RS02250

    Small Interfering RNA (siRNA) CD47 Others

    CD47 Human Pre-designed siRNA Set A contains three designed siRNAs for CD47 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CD47 Human Pre-designed siRNA Set A
    CD47 Human Pre-designed siRNA Set A
  • HY-143224

    CD47 Cancer
    NCGC00138783 is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 µM. NCGC00138783 directly blocks the interaction between CD47 and SIRPα axis .
    NCGC00138783
  • HY-143224A

    CD47 Cancer
    NCGC00138783 free base is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 µM. NCGC00138783 free base directly blocks the interaction between CD47 and SIRPα axis .
    NCGC00138783 free base
  • HY-P10420

    CD47 Interleukin Related Cancer
    RS17 is an anti-tumor peptide designed to bind specifically to the CD47 molecule and block the interaction between CD47 and its ligand, SIRPα, on the surface membrane of macrophages. The main regulatory mechanism of RS17 is to prevent CD47 from transmitting selective phagocytosis signals to SIRPα by binding to CD47, so that macrophages do not recognize tumor cells as their own tissue, but phagocytose them as foreign substances, thereby inhibiting immune escape of tumor cells. RS17 can be used to study the mechanism of anti-tumor response and immune escape .
    RS17
  • HY-P99777

    TTI-621

    CD47 Cancer
    Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .
    Ontorpacept
  • HY-143225

    CD47 Others
    NCGC00538431 is a potent modulator of SIRPα-CD47 .
    NCGC00538431
  • HY-P3968

    CD47 Others
    Thrombospondin-1 (1016-1021) (human, bovine, mouse), a Thrombospondin-1-derived peptide, is a truncated peptide devoid of CD47-binding activity .
    Thrombospondin-1 (1016-1021) (human, bovine, mouse)
  • HY-P990694

    TG-1801

    CD19 CD47 Inflammation/Immunology
    Zeripatamig is an anti-CD19/CD47 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Zeripatamig
  • HY-P99029
    Magrolimab
    1 Publications Verification

    Hu5F9-G4

    CD47 Cancer
    Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer .
    Magrolimab
  • HY-P99026

    TJ011133; TJC4

    CD47 Cancer
    Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity .
    Lemzoparlimab
  • HY-P0144

    CD47 Apoptosis Inflammation/Immunology
    Thrombospondin-1 (1016-1023) (human, bovine, mouse), is the C-terminal end of the native sequence of Thrombospondin-1 (TSP-1), is a CD47 agonist peptide .
    Thrombospondin-1 (1016-1023) (human, bovine, mouse)
  • HY-P99706

    AK 117

    CD47 Interleukin Related Cancer
    Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .
    Ligufalimab
  • HY-151132

    IsoQC-IN-1

    CD47 Cancer
    Glutaminyl cyclases-IN-1 (IsoQC-IN-1) is a potent glutaminyl cyclases (QC) inhibitor with IC50 values of 12 nM and 73 nM for human QC and isoQC, respectively. Glutaminyl cyclases-IN-1 can selectively interfere with the interaction of CD47/SIRPα through isoQC inhibition, and enhances the increased phagocytic activity of both THP-1 and U937 macrophages .
    Glutaminyl cyclases-IN-1
  • HY-P10388

    CD47 TGF-β Receptor Cancer
    TAX2 peptide is a dodecapeptide based on molecular docking and simulation design, derived from the cell surface receptor CD47 sequence. TAX2 peptide acts as a selective antagonist of TSP-1 (thromboxin-1) interacting with CD47. TAX2 peptide can promote the binding of TSP-1 to CD36, which leads to the destruction of VEGFR2 (vascular endothelial growth factor receptor 2) activation, thereby blocking downstream NO (nitric oxide) signaling, demonstrating anti-angiogenic properties. TAX2 peptide can be used to study angiogenesis and tumor cell interactions in the tumor microenvironment .
    TAX2 peptide
  • HY-P99175

    CD47 Cancer
    KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research .
    KWAR 23
  • HY-P3970

    TGF-β Receptor Inflammation/Immunology
    KRFK, a peptide derived from TSP-1, can activate TGF-β. KRFK promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors such as CD47 and CD36. KRFK can be used for chronic ocular surface inflammatory disorders reseach .
    KRFK
  • HY-P3970A
    KRFK TFA
    2 Publications Verification

    TGF-β Receptor Inflammation/Immunology
    KRFK TFA, a peptide derived from TSP-1, can activate TGF-β. KRFK TFA promotes TGF-β-mediated signaling and its downstream role, independent of thrombospondin (TSP) receptors such as CD47 and CD36. KRFK TFA can be used for chronic ocular surface inflammatory disorders reseach .
    KRFK TFA
  • HY-120284

    Others Cancer
    CCCI-01 is a centrosome clustering inhibitor. CCCI-01 has selective effects on cancer. CCCI-01 can be used for the research of non-cross-resistant anti-cancer agents with blocking centrosome clustering .
    CCCI-01
  • HY-116681

    Others Infection
    Aflavarin is produced from cluster 39 expressed mainly in sclerotia. Aflavarin exhibits anti-insectan activity .
    Aflavarin
  • HY-P990033

    CC-95251; BMS-986351

    CD47 Cancer
    Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPα antibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research .
    Anzurstobart
  • HY-16438
    RRx-001
    10+ Cited Publications

    CD47 Apoptosis Parasite Infection Inflammation/Immunology Cancer
    RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity . RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α . RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity .
    RRx-001
  • HY-P99021

    LY 2951742

    CGRP Receptor Neurological Disease
    Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .
    Galcanezumab
  • HY-156533A

    5-HT Receptor Neurological Disease Inflammation/Immunology Cancer
    5-HT2 agonist-1 (Compound 24) free base is a 5-HT2A & 5-HT2B & 5-HT2C agonist, with IC50s of 10 nM, 8.3, and 1.6 nM respectively. 5-HT2 agonist-1 free base can be used for research of depression, alcoholism, tobacco and cocaine addiction, inflammation, cluster headache, PTSD, seizure disorders and other CNS disorders .
    5-HT2 agonist-1 free base
  • HY-156533

    5-HT Receptor Cancer
    5-HT2 agonist-1 (Compound 24) is a 5-HT2A & 5-HT2B & 5-HT2C agonist, with IC50s of 10 nM, 8.3, and 1.6 nM respectively. 5-HT2 agonist-1 free base can be used for research of depression, alcoholism, tobacco and cocaine addiction, inflammation, cluster headache, PTSD, seizure disorders and other CNS disorders .
    5-HT2 agonist-1
  • HY-12797

    Others Cancer
    GF 15 is a potent inhibitor of centrosomal clustering in tumor cells.
    GF 15
  • HY-156534

    5-HT Receptor Neurological Disease Inflammation/Immunology Cancer
    5-HT2A&5-HT2C agonist-1 (Example 2) is a 5-HT2A & 5-HT2C agonist, with IC50s of 196 nM and 0.9 nM respectively. 5-HT2A&5-HT2C agonist-1 can be used for research of depression, alcoholism, tobacco and cocaine addiction, inflammation, cluster headache, PTSD, seizure disorders and other CNS disorders .
    5-HT2A&5-HT2C agonist-1
  • HY-P5984

    mTOR Others
    Thioether-cyclized helix B peptide, CHBP can improve metabolic stability and renoprotective effect through inducing autophagy via inhibition of mTORC1 and activation of mTORC2 .
    Thioether-cyclized helix B peptide, CHBP
  • HY-P5984A

    mTOR Others
    Thioether-cyclized helix B peptide, CHBP (TFA) is the TFA form of Thioether-cyclized helix B peptide, CHBP (HY-P5984). Thioether-cyclized helix B peptide, CHBP (TFA) can improve metabolic stability and renoprotective effect through inducing autophagy via inhibition of mTORC1 and activation of mTORC2 .
    Thioether-cyclized helix B peptide, CHBP TFA
  • HY-131967

    CD73 Inflammation/Immunology Cancer
    CD73-IN-4 is a potent and selective methylenephosphonic acid CD73 inhibitor, with an IC50 of 2.6 nM for human CD73. CD73-IN-4 is potential for the research of cancer immunology .
    CD73-IN-4
  • HY-12040
    Elesclomol
    40+ Cited Publications

    STA-4783

    Reactive Oxygen Species Apoptosis Cuproptosis Cancer
    Elesclomol (STA-4783) is a potent copper ionophore and promotes copper-dependent cell death (cuproptosis). Elesclomol specifically binds ferredoxin 1 (FDX1) α2/α3 helices and β5 strand. Elesclomol inhibits FDX1-mediated Fe-S cluster biosynthesis. Elesclomol is an oxidative stress inducer that induces cancer cell apoptosis. Elesclomol is a reactive oxygen species (ROS) inducer. Elesclomol can be used for Menkes and associated disorders of hereditary copper deficiency research .
    Elesclomol
  • HY-P10106

    PAK Cancer
    TAT-PAK18 inhibitory peptide is a membrane-permeable PAK inhibitory peptide. TAT-PAK18 inhibitory peptide reduces F-actin clusters and occludes the effect of Shank3 knockdown .
    TAT-PAK18 inhibitory peptide
  • HY-12518
    OF-1
    3 Publications Verification

    Epigenetic Reader Domain Cancer
    OF-1 is a potent pan-BRPF bromodomain (BRD) inhibitor, with IC50 values of 270 nM, 1.2 μM for TRIM24 and BRPF1B, respectively .
    OF-1
  • HY-I0726

    Others Infection
    Enantiomer of Sofosbuvir is an enantiomer of Sofosbuvir, a prescription medicine for the treatment of patients with chronic hepatitis C. There is no biological activity report on enantiomer of Sofosbuvir until now.
    Enantiomer of Sofosbuvir
  • HY-145795

    Liposome Others
    OF-02 is an alkenyl amino alcohol (AAA) ionizable lipid for highly potent in vivo mRNA delivery.
    OF-02
  • HY-121034

    Others Others
    Acaterin is a compound isolated from Pseudomonas. Its biosynthetic gene cluster has been identified, and related studies have proposed its biosynthetic pathway. Comparative transcriptomics has shown that its formation is related to the bacterial regulatory network.
    Acaterin
  • HY-146146

    KAA

    Kinesin Cancer
    Kolavenic acid analog (KAA) is an anticancer agent. Kolavenic acid analog shows strong activity against HSET-overproducing yeast cells. Kolavenic acid analog inhibits centrosome clustering in human cancer cells containing high HSET levels and supernumerary centrosomes .
    Kolavenic acid analog
  • HY-W250128

    DDSA (mixture of isomers)

    Biochemical Assay Reagents Others
    2-Dodecen-1-Ylsuccinic Anhydride is a biochemical reagent that can be used as a biological material or organic compound for life science related research. Dodecenylsuccinic anhydride (mixture of isomers) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Dodecenylsuccinic anhydride (mixture of isomers)
  • HY-18377

    DR5 Activator

    TNF Receptor Apoptosis Cancer
    Bioymifi (DR5 Activator), a potent TRAIL receptor DR5 activator, binds to the extracellular domain (ECD) of DR5 with a Kd of 1.2 μM. Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis .
    Bioymifi
  • HY-76937

    VD/VDR Endocrinology
    Impurity of Doxercalciferol is an impurity of doxercalciferol, which is a synthetic analog of ergocalciferol (vitamin D2), used as a agent for secondary hyperparathyroidism and metabolic bone disease, and it suppresses parathyroid synthesis and secretion.
    Impurity of Doxercalciferol
  • HY-134782

    Liposome Others
    OF-Deg-Lin is an ionizable amino lipid used for the generation of Lipid nanoparticles (LNPs).
    OF-Deg-Lin
  • HY-118090

    Others Others
    L-γ-Glutamyl-L-glutamic acid is the isomer of D-γ-Glutamyl-D-glutamic acid (HY-118090A), and can be used as an experimental control. D-γ-Glutamyl-D-glutamic acid is a poly(γ-glutamic acid) of clusters of D- and D-glutamic acid repeating units in a linear chain .
    L-γ-Glutamyl-L-glutamic acid
  • HY-149035

    Others Cancer
    PAA4 is a methide carbon-centered polynuclear Au(I) clusters. PAA4 shows antiproliferative activity. PAA4 increases the expression of pH2AX in a time dependent manner. PAA4 shows anti-tumor effect in orthotopic bladder cancer mouse model .
    PAA4
  • HY-149036

    Ferroptosis Endogenous Metabolite Reactive Oxygen Species Cancer
    PAA5 is a methide carbon-centered polynuclear Au(I) cluster. PAA5 can release Au(I) causing Pro-oxidant response and accelerated ferroptosis. PAA5 increases the expression of pH2AX in a time-dependent manner. PAA5 has anticancer activity .
    PAA5
  • HY-15265

    VD/VDR Cancer
    Impurity F of Calcipotriol; Calcipotriol (MC 903; Calcipotriene) is a ligand of VDR-like receptors.
    Impurity F of Calcipotriol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: